drugset / Trial / NCT00065611

Steroid Treatment for Kidney Disease

NCT00065611 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine. Approximately half of FSGS patients will lose kidney function within 8 years of diagnosis and will require dialysis. The purpose of this study is to determine whether intermittent oral steroid therapy can cause sustained remission of FSGS and MCD. Approximately 70 participants, including adults and children older than age 2, will be enrolled in this study. They will receive 48 doses of oral dexamethasone over a period of 48 weeks. One group will take two daily doses every 2 weeks; the other group will take four daily doses every 4 weeks. Doctors will monitor participants before, during, and after the steroid treatment with extensive exams and testing. At the completion of the study, researchers will evaluate the safety and efficacy of the drug treatment.

Timeline

Start
2003-07
Primary completion
2010-08
Completion
2010-08

Outcome

Missed primary endpoint

registry analysis (superiority or other test); 2 Doses Every 2 Weeks Arm vs 4 Doses Every 4 Weeks Arm; p = 0.9074; Chi-squared NCT00065611 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 25 mg/m2 Oral